| J01M A02 Ciprofloksacin - N06B C01 Koffein |
ATC1 | J01M A02 Ciprofloksacin (Ciprofloxacin) |
ATC2 | N06B C01 Koffein (Caffeine) |
Nivå | Akademisk interesse. (les mer...) |
Konsekvens | Økt konsentrasjon av koffein (50-100 %). |
Mekanisme | Ciprofloksacin hemmer metabolismen av koffein via CYP1A2. |
Grunnlag | Interaksjonsstudier |
Referanser |
1. | Barnett G, Segura J, de la Torre R et al. Pharmacokinetic determination of relative potency of quinolone inhibition of caffeine disposition. Eur J Clin Pharmacol 1990; 39: 63–9. Les mer... |
2. | Harder S, Staib AH, Beer C et al. 4-Quinolones inhibit biotransformation of caffeine. Eur J Clin Pharmacol 1988; 35: 651-6. Les mer... |
3. | Nicolau DP, Nightingale CH, Tessier PR et al. The effect of fleroxacin and ciprofloxacin on the pharmacokinetics of multiple dose caffeine. Drugs 1995; 49 (suppl. 2): 357-9. Les mer... |
4. | Kim M-Y, Nightingale CH, Nicolau DP. Influence of sex on the pharmacokinetic interaction of fleroxacin and ciprofloxacin with caffeine. Clin Pharmacokinet 2003; 42: 985–96. Les mer... |